FATE vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

FATE

46.4
AI Score
VS
CDNA Wins

CDNA

50.7
AI Score

Investment Advisor Scores

FATE

46score
Recommendation
HOLD

CDNA

51score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric FATE CDNA Winner
Forward P/E 0 94.3396 Tie
PEG Ratio 0 -0.12 Tie
Revenue Growth -20.3% 52.2% CDNA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 46.4/100 50.7/100 CDNA
Profit Margin 0.0% 24.2% CDNA
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

FATE 1M: -14.4% · 3M: +63.4% CDNA 1M: +63.9% · 3M: +122.6%

Current Technical Phase

FATE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 48.5 · Price: $2.50

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (24.8% over 20 days), RSI 81

RSI (14): 81.5 · Price: $47.85

Fundamentals Snapshot

Metric FATE CDNA
Market Cap
Forward P/E -2.5 37.2
Trailing P/E 21.0
Revenue (TTM)
Revenue Growth -0.2% 0.5%
Gross Margin -12.8% 0.7%
Operating Margin -25.4% 0.0%
EPS -1.09 2.08
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, CDNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.